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Elevated urinary excretion of the C5b.9 complex in membranous
nephropathy. In experimental membranous nephropathy, antibody
binding to glomerular epithelial cell membrane antigens results in
complement activation and formation of complement C5b-9 membrane
attack complexes in glomeruli. During active disease, the C5b-9 com-
plexes are shed into the urine. To test the hypothesis that a similar
mechanism might be operative in human membranous nephropathy, we
measured urinary excretion of C5b-9 and CS in 146 proteinuric patients
with biopsy-proven glomerular diseases or diabetes mellitus. Urinary
excretion of C5b-9 relative to CS excretion was higher in 40 patients
with membranous nephropathy than in 106 patients with proteinuria due
to non-membranous glomerulonephritis when analyzed by covariance
analysis (P < 0.0002). Urinary C5b-9 excretion was higher in membra-
nous nephropathy than in membranoproliferative glomerulonephritis (N
= 13, P < 0.05), minimal change-focal sclerosis (N = 33, P < 0.001),
mesangial proliferative glomerulonephritis (N = 9, P < 0.02) and IgA
nephropathy (N = 7, P < 0.025). Urinary C5b-9 excretion was also
higher in patients with lupus nephritis (N = 18, P < 0.02) compared to
those with non-membranous glomerulonephritis. The lupus patients
with the highest excretion had clinical or pathological features of
membranous nephropathy. Nine patients with membranous nephrop-
athy and elevated urinary C5b-9 excretion had a shorter duration of
disease (P < 0.05), lower serum creatinine levels (P < 0.05) and more
proteinuria (P < 0.02) than the 31 membranous nephropathy patients
with normal values. The finding of increased urinary CSb-9 excretion in
a subset of patients with idiopathic or lupus membranous nephropathy
suggests an autoimmune basis for glomerular disease in these patients,
and may indicate that these patients have ongoing immune deposit
formation.
Membranous nephropathy is the most common cause of
idiopathic nephrotic syndrome in adults and is characterized by
subepithelial deposits of immunoglobulin, C3 and C5b-9 in a
finely granular pattern [1]. The antigen to which these deposited
antibodies is directed has not been identified in humans. In rats,
an identical lesion is induced by deposition of antibody directed
against antigen(s) expressed on the membrane of the glomerular
epithelial cell (Heymann nephritis) [2]. Proteinuria in Heymann
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nephritis is mediated by epithelial cell membrane insertion of
the CSb-9 membrane attack complex [3, 4] which is endocy-
tosed, transported intracellularly and then exocytosed in the
urinary space [5]. Urinary C5b-9 excretion occurs only when
subepithelial deposits result from antibody binding to the epi-
thelial cell [6], and urinary C5b-9 excretion closely parallels
ongoing glomerular immune deposit formation and therefore
disease activity [6, 7].
We reasoned that if a similar autoimmune mechanism medi-
ates membranous nephropathy in humans, a subset of patients
with active disease should exhibit increased urinary C5b-9
excretion that might serve as a non-invasive measure of disease
activity. Our findings demonstrate the urinary C5b-9 excretion
significantly exceeds expected values in patients with membra-
nous nephropathy compared to patients 'with several other
proteinuric glomerular diseases. Moreover, patients with ele-
vated urinary C5b-9 excretion have more proteinuria, a shorter
duration of disease and better renal function than patients with
normal urinary C5b-9 values, suggesting that increased urinary
C5b-9 excretion may be a marker of disease activity.
Methods
Urine sample collection
We analyzed random urine specimens obtained for routine
testing from 38 normal subjects and 146 patients (54 woman, 92
men, mean age 38.4 years; range 3 to 76 years) with proteinuria
due to a variety of glomerular diseases. Proteinuria was defined
as a ratio of protein to creatinine concentrations exceeding
0.022 mg/zmol creatinine (0.2 mg/mg). With the exception of
those patients with diabetes mellitus and nephropathy and two
patients with lupus nephritis, all patients had diagnoses of
glomerular disease documented by renal biopsy. Disease dura-
tion at the time of study in patients with membranous nephrop-
athy was defined as the time in months from the onset of
documented proteinuria or, if this was not known, from the time
of renal biopsy to the time of urine sample collection. All other
clinical parameters were measured at the time of urine sample
collection. Freshly voided urine was mixed 9:1 vol/vol with
Tris-HC1 pH 8.6 buffer containing 0.1% NaN3 (wt/vol), 100 mri
bezamidine, 100 mr.t epsilon-amino-caproic acid (EACA, Sigma
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Fig. 1. Characterization of the monoclonal antibody (N20/9) to C5b.
Purified C5 (I gIlane) was electrophoresed on SDS-PAGE under
non-reducing conditions (lane a, c) and under reducing conditions (lane
b, d). Lanes a and b were stained with Commassie blue, lanes c and d
were blotted to NC-membranes and probed with the monoclonal
antibody N20/9. The antibody reacted with CS (lane c) and the beta-
chain of reduced C5 (lane d).
Chemical Co., St. Louis, Missouri, USA), 200 mr'i EDTA,
aprotinin (100 kallikrein inhibitor U/mi) and 0.5% Tween 20
(vol/vol), and stored at 4°C. C5b-9 in proteinuric urine was
stable under these conditions for over one year. Urine protein
was determined by precipitation with sulfosalicylic acid and
creatinine by the picric acid method (Worthington Diagnostics,
Freehold, New York, USA).
Preparation and characterization of antibodies to human
C5a, C5b, C6, C9 and C5b-9 neoantigen
Immunoglobulin (IgG) fractions of monospecific goat antisera
against the human complement components C6 and C9 (Gen-
zyme, Boston, Massachusetts) were biotinylated using biotin-
X-NHS (Calbiochem, La Jolla, California, USA) as described
elsewhere [6, 8].
For ELISAs, monoclonal antibodies to CSa, to the CS
beta-chain detecting the C5b moiety of CS, and to C5b-9
neoantigen were prepared using standard protocols [81. The
monoclonal antibody to human C5a (F241l) was raised by
immunization with purified C5a and characterized as described
previously [9]. A monoclonal antibody (N20/9) to CS was raised
by immunization with purified C5 and biotinylated as described
elsewhere [8—10]. By SDS-PAGE and immunoblotting [11, 12],
this antibody reacted with purified intact human CS (Fig. 1, lane
c) and with the beta-chain of C5 after reduction with DTT (Fig.
1, lane d), and was therefore specific for the C5b-moiety of C5.
The monoclonal antibody (W13/15) reacted with C9 obtained
from human complement lysed rabbit erythrocytes prepared as
described by Biesecker et al 113] (Fig. 2, lane b), but not with
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Fig. 2. Characterization of the monoclonal antibody W13/15 to a
neoantigen on human C9. Normal human EDTA-plasma (1 p1, lanes a,
d) and human complement-lysed rabbit erythrocytes (10 p1, lanes b, c)
were separated by SDS-PAGE and transferred to NC-membranes.
Lanes a and b were incubated with the monoclonal antibody Wl3/15,
lanes c and d were incubated with polyclonal antibody to human C9
(Genzyme). The monoclonal antibody W13/15 bound to the same band
in erythrocyte ghosts (lane b) as did the polyclonal antibody to human
C9 (lane c) but did not react with native C9 in normal EDTA-plasma
(lane a). C9 in normal EDTA-plasma did react with the polyclonal to C9
(lane d). These data indicate reactivity of the monoclonal antibody
W13115 with a neoantigen of C9 expressed in the C5b-9 complex. The
high molecular weight bands at 200 kD (lanes b, c) were not detectable
after reduction of the samples with DTT and probably represent
disulfide bond linked multimers of C9 or poly C9.
native C9 in EDTA-plasma (Fig. 2, lane a), and was therefore
reactive with a CSb-9 neoantigen.
Monoclonal antibody binding to plasma proteins (Figs. 1 and
2) separated by SDS-PAGE [11] was studied by immunoblotting
[12] using biotinylanted sheep antibody to mouse IgG (Amer-
sham, Arlington Heights, Illinois, USA), streptavidin-peroxi-
dase, and the peroxidase substrate 4-chloro-1-naphtole [8].
Measurement of urinary excretion of C5b-9
The C5b-9 ELISA was performed on microtitration plates
(Dynatech, Chantilly, Virginia, USA; NUNC, Roskilde, Den-
mark) coated with the monoclonal antibody (W131l5) to human
C9 neoantigen as capturing antibody. Nonspecific binding was
blocked by incubation of the plates with 0.2% casein (Sigma)
and by pre-incubating urine samples with heat-aggregated
(63°C, 6 hrs) goat IgG (1.6 mg/mI urine) for 30 minutes. For
C5b-9 detection wells were incubated with biotinylated poly-
clonal anti-human C6 antibody, 2 gig/well, washed and then
incubated with streptavidin-peroxidase (Amersham). Color was
developed with 2.2'-azinodi-(3-ethyl-benzthiazolinesulfonate)
(ABTS) (Boehringer Mannheim) and 2.5 msi H202 and read at
405 nm using a microplate reader (Dynatech MR 560). The
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Table 1. Urinary protein, C5b-9 and CS excretion and mean urinary C5b-9/C5 ratios in pati
glomerular diseases
ents with membranous nephropathy and other
N
(elevated!
Urinary values Mean
C5/creatinine C5b-9/C5 P valuebProtein/creatinine C5b-9/creatinine
Disease group normal) mg/.,imol p.g/p.mol p.g/,umol ratioa group vs. MN
Membranous nephropathy 9/40 0.96 0.75 0.32 0.66 0.31 0.86 5.40 20.59
Membranoproliferative glomerulonephritis 1/13 0.57 0.53 0.10 0.15 0.20 0.49 1.35 2.24 0.047
Minimal change/focal sclerosis 0/33 1.11 1.32 0.08 0.18 0.09 0.18 0.75 0.97 0.001
Mesangial proliferative glomerulonephritis 0/9 0.88 0.41 0.05 0.06 0.16 0.40 0.71 0.98 0.014
IgA nephropathy 0/7 0.89 0.84 0.04 0.04 0.05 0.05 0.92 0.79 0.020
Lupus nephritis 4/18 1.23 3.30 0.06 0.11 0.03 0.04 2.24 3.34 0.371
Diabetic nephropathy 0/9 1.57 1.32 0.62 0.82 1.64 2.51 0.53 0.49 0.096
Rapid progressive glomerulonephritis 0/8 0.60 0.54 0.08 0.10 0.08 0.10 1.31 1.25 0.226
Miscellaneous 1/9 1.11 1.66 0.27 0.70 0.22 0.52 1.47 2.20 0.052
a Values derived from the mean of values in individual patients
b Differences between groups determined by co-variance analysis
C5b-9 assay was calibrated using a standard human zymosan-
activated serum, provided by Dr. Thomas Lint, Rush Presby-
terian St. Lukes Medical Center, Chicago, Illinois, USA. The
assay had a detection limit of 45 ng C5b-9/ml.
Measurement of urinary excretion of C5
Excretion of CS was measured in all urine samples by ELISA
using the anti-C5a monoclonal antibody (F24/l) as a capturing
antibody and biotinylated anti-C5b antibody (N20/9) as the
detecting antibody. The ELISA to C5 was standardized using
EDTA-plasma calibrated with purified C5 [101 and had a detec-
tion limit of 60 ng/ml [141.
Data analysis
Concentrations of C5b-9, C5, total protein and creatinine
were measured in each urine sample. To include samples with
no detectable C5 or C5b-9, a constant of 0.03 g/ml was added
to all C5 and C5b-9 values. To correct for differences in urine
concentration, values of C5b-9 and CS were expressed per tmol
of creatinine and the skewness of the data was reduced by
conversion to logarithms. Comparisons of the urinary C5b-9/
creatinine and C5/creatinine ratios between groups were done
by Wilcoxon rank sum test [15].
C5b-9 was found in most proteinuric urines, suggesting some
spontaneous formation of C5b-9 from native complement com-
ponents in post-glomerular proteinuric urine. To correct for
this, measured C5b-9 excretion was compared to expected
C5b-9 excretion determined from a regression line that related
C5b-9 excretion to CS excretion. The rationale for relating
C5b-9 excretion to C5 rather than total protein is presented
below in results. To determine if there was a significant differ-
ence between measured and expected values for urinary C5b-9
excretion in the group of patients with membranous nephrop-
athy compared to other groups, co-variance analysis of urinary
C5b-9/creatinine was performed using urinary C5/creatinine as
the covariate and employing the SSPS statistical package
(SSPS, V2.0, Chicago, Illinois, USA) [161. Differences were
considered significant if analysis of variance yielded a P value
of < 0.05 [16).
To determine if urinary C5b-9 excretion in individual patients
was elevated above expected values based on CS excretion, we
used a standard formula to plot a regression line between log
transformed values of urinary C5b-9/creatinine and C5/creati-
nine using data from all patients except those with membranous
nephropathy or lupus nephritis, the two groups with elevated
urinary C5b-9 excretion. We then measured the distance of
each individual value from the regression line in standard
deviations of Student's t-distribution (standardized residuals)
[161. Individual values were regarded as elevated if they
equaled or exceeded 1.65, a value indicating a 95% probability
that the result was elevated above the mean of the regression
line using a single tailed test [16].
We used Student's t-tests to compare proteinuria, serum
creatinine values and time from onset of disease between
patients with membranous nephropathy with elevated and those
with "normal" urinary C5b-9 excretion. Tests to compare
serum creatinine and time from onset of disease were per-
formed on the logarithms of the data to account for variance
in-homogeneity. With the exception indicated above, two-tailed
tests were used in all statistical comparisons. P values < 0.05
were considered significant.
Results
Urine c5b-9, C5 and protein excretion in patients with
glomerular disease
The urinary protein/creatinine, total C5b-9/creatinine and
C5/creatinine ratios for each group are shown in Table 1. No
C5b-9 was detected in the urine samples from 38 normal
subjects. Urinary C5b-9 was detectable in most patients who
had a urinary protein/creatinine ratio greater than 0.34 mg/mol
(3.0 mg protein/mg creatinine). The mean urinary C5b-9 con-
centration was significantly higher (P < 0.004) in patients with
membranous riephropathy than in patients with non-membra-
nous nephropathy. This value was also higher (P < 0.02) in
patients with diabetic nephropathy compared to non-diabetic
patients.
The presence of C5b-9 in urine from most patients with
proteinuria, and the weak relationship between urine C5b-9
excretion and urinary protein excretion (r = 0.29, P < 0.001),
suggested that some spontaneous generation of C5b-9 may
occur from native complement components in urine after filtra-
tion and before collection in protease inhibitors. If so, differ-
ences in urinary C5b-9 excretion could simply reflect differ-
ences in total protein excretion between disease groups. To
account for this possibility, the urinary C5b-9 values were
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Fig. 3. Urinary C5b-9 excretion in membranous nephropathy. Urinary
C5b-9and C5 excretion for patients with membranous nephropathy (N
= 40) is indicated with solid circles. The data are superimposed on the
regression line (asterisk) and the 90% prediction limits (open circles)
derived from all non-membranous, non-lupus patients (N 88).
related to urinary C5 excretion. Urinary C5 was selected rather
than total urinary protein or the urinary content of some other
plasma protein for several reasons. Of all components of the
C5b-9 complex, C5 has the highest molecular weight, and
therefore, it should have the lowest fractional clearance. As
proteolytic cleavage of C5 also initiates the formation the C5b-9
complex it should represent the limiting factor for generation of
C5b-9 in urine. The correlation between the urinary C5b-9 and
C5 excretion (r = 0.80, P < 0.001) also was stronger than
between urinary C5b-9 and urinary protein excretion, Using
co-variance analysis, the log of urinary C5b-9/creatinine in
membranous nephropathy was therefore compared with the
non-membranous group as a whole and with individual disease
groups, with log C5/creatinine as the covariate. The membra-
nous group exhibited significantly elevated urinary C5-9 excre-
tion compared to all non-membranous patients (P < 0.002) and
also compared to individual groups of patients with membrano-
proliferative glomerulonephritis (P < 0.05), minimal change!
focal sclerosis (P < 0.001), mesangial proliferative glomerulo-
nephritis (P < 0.02) and IgA nephropathy (P < 0.025). Urinary
C5b-9 excretion was also higher than expected based on C5
excretion in patients with membranous nephropathy compared
to patients with diabetes, rapidly progressive glomerulonephri-
tis and a group of miscellaneous glomerular diseases, but these
differences did not reach statistical significance.
Similar co-variance analysis revealed that urinary C5b-9
excretion was also elevated in the group of patients with lupus
nephritis compared to non-membranous nephrotic patients (P <
0.02), but not in other disease groups.
When values in individual patients were analyzed for their
Table 2. Serum creatinine, protein/creatinine ratios and time from
onset of disease at time of study in membranous nephropathy
patients with normal and elevated urinary C5b-9 excretion
Time from onset
Serum Protein! of disease
creatinine creatinine years
Group N imoIIliter mglp.mol Mean Range
Elevated 9 99.2 20.2a 1.48 072b l.0 0.1—5.0
Normal 31 171.1 108.6 0.82 0.70 3.8 0.17—16.0
All data are mean SD
a < 0.05
h p < 0.02
distance from a regression line relating C5b-9 to C5 excretion in
non-membranous, non-lupus patients, nine patients in the mem-
branous group had values above 1.65 standard deviations (Fig.
3) indicating a 95% probability that urinary C5b-9 excretion was
elevated above expected values. Four patients with lupus
nephritis also had elevated values by this criteria. Two of these
patients had biopsy-proven membranous glomerular lesions and
two had severe steroid-resident nephrotic syndrome with nor-
mal renal function and were suspected on a clinical basis to
have membranous lesions [171. One patient with a membrano-
proliferative glomerulonephritis and subepithelial immune de-
posits by electron microscopy, and one patient with a mesangial
capillary lesion in the miscellaneous group also had elevated
individual urinary C5b-9 excretions. All other patients tested
had values within 1.65 standard deviations of the mean pre-
dicted amount of C5b-9.
Clinical characteristics
Table 2 shows the clinical characteristics of the nine patients
with membranous nephropathy who had elevated C5b-9 excre-
tion compared to the 31 membranous patients with normal
values. The mean duration of disease at the time of study in the
patients with elevated C5b-9 excretion was shorter than in the
other patients (1.0 years, range 0.1 to five years; vs. 3.8 years,
range 0.2 to 16 years, P < 0.05). Patients with elevated values
also had more proteinuria (protein to creatinine ratio 1.48
0.72 mg'mol vs. 0.82 0.70 mg!mol, P < 0.02) and better
renal function (serum creatinine 99.2 20.2 /Lmol/liter vs. 171
108.6 fLmol/liter, P < 0.05).
Discussion
These results demonstrate that proteinuric patients excrete
detectable amounts of C5b-9 complexes regardless of their
underlying glomerular disease, and in diseases where glomeru-
lar complement deposits are not routinely detected by immu-
nofluorescence. The size of the C5b-9 complex (1000 kD)
suggests that its filtration should be negligible, a contention
supported by experimental studies [6, 18]. Thus, in humans
some assembly of C5b-9 from filtered native components must
occur in the urine. Because CS (200 kD) is the largest compo-
nent of the precursors of the C5b-9 complex, the urinary C5
concentration should be the factor limiting the generation of
C5b-9 in urine. We therefore related the urinary C5b-9 values to
the urinary CS values to identify C5b-9 excretion above that
.
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which might occur spontaneously due to filtered native comple-
ment components. Using covariance analysis we found a sig-
nificant increase of urinary C5b-9 excretion in patients with
membranous nephropathy compared to all non-membranous
patients with nephrotic syndrome. Urinary C5b-9 excretion was
also elevated in patients with membranous nephropathy com-
pared to groups of patients with other common causes of
proteinuria including membranoproliferative glomerulonephri-
tis, minimal change/focal sclerosis, mesangial proliferative gb-
merulonephritis and IgA nephropathy. Although the values for
urinary C5b-9 excretion in membranous nephropathy were also
higher than those in patients with diabetes, rapidly progressive
glomerulonephritis and a miscellaneous group of glomerular
diseases, these differences did not reach statistical significance.
The finding of increased urinary C5b-9 excretion was not
entirely specific for membranous nephropathy nor were the
values increased in all patients with membranous nephropathy.
Among the 106 patients with non-membranous nephropathy
studied, six had elevated values. Four of these patients had
lupus nephritis, and two had biopsy-proven membranous gb-
merular lesions. The other two lupus patients had developed
severe steroid-resistant nephrotic syndrome several years after
biopsies had revealed mild-diffuse proliferative glomerulone-
phritis. They were therefore suspected clinically to have mem-
branous lesions [17]. Five other patients with known membra-
nous lupus nephritis and nine patients with other forms of lupus
nephritis of varying severity did not have elevated values,
although glomerular C5b-9 deposits and elevated circulating
C5b-9 levels are commonly found in such patients [19, 201. This
observation suggests that the mechanism by which subepithelial
deposits are formed in some patients with membranous lupus
nephritis may be similar to that in some patients with idiopathic
membranous nephropathy.
This finding of elevated urinary C5b-9 excretion in some
patients with membranous nephropathy supports the hypothe-
sis that the pathogenesis of this disease may be similar to that
defined in the Heymann nephritis models in rats [I]. In Hey-
mann nephritis, subepithelial deposits of IgG and complement
result from antibody binding to an antigen(s) of the glomerular
epithelial cell membrane, and C5b-9 assembly and membrane
insertion is required for proteinuria to develop [reviewed in 1].
Studies of a variety of models of immune and non-immune
glomerular disease have shown that increased urinary C5b-9
excretion occurs only in membranous nephropathy induced by
antibodies to glomerular epithelial cell antigens and it does not
occur when glomerular immune complex or C5b-9 deposits
result from other mechanisms [6]. The mechanism of urinary
C5b-9 excretion appears to involve endocytosis of membrane-
inserted C5b-9 complexes by glomerular epithelial cells fol-
lowed by transcellular transport and exocytosis into the urinary
space [5]. In rats, urinary C5b-9 excretion ceases immediately
following cessation of antibody deposition, despite persistence
of proteinuria, and thus serves as a sensitive index of disease
activity [6, 7]. Thus one implication of our findings is that the
pathogenesis of membranous nephropathy in humans, at least
in a subset of patients, involves an autoimmune mechanism.
Our data further suggest that a similar mechanism may be
operative in some patients with lupus membranous nephrop-
athy.
Our findings do not exclude the possibility that most, or even
all, patients with idiopathic membranous nephropathy have a
similar mechanism operative, but that antibody deposition was
not ongoing at the time of study in many patients. Patients were
studied randomly and often not during early or active disease.
The observations that patients with elevated urinary C5b-9
excretion had significantly more proteinuria as well as a shorter
duration of disease when studied are consistent with the possi-
bility that urinary C5b-9 excretion may provide a non-invasive
index of disease activity in membranous nephropathy in hu-
mans as it does in rats. This finding may be of clinical utility in
human membranous nephropathy. In membranous nephrop-
athy the pathogenic antibody has not been identified and
therefore cannot be measured, proteinuria is variable and
poorly responsive to therapy initially, and therapy is potentially
toxic and probably indicated only in certain patients expected
to have progressive disease [7, 21—23]. Further studies will be
required to establish the relationship between urinary C5b-9
excretion and prognosis or response to therapy.
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